Skip to content

Efficacy of Intense Pulsed Light combined with emedastine difumarate eye drops in the treatment of Allergic Conjunctivitis and analysis of the impact on Cytokine Levels in Tears (IL-4, IL-5, IL-13)

Efficacy of Intense Pulsed Light combined with emedastine difumarate eye drops in the treatment of Allergic Conjunctivitis and analysis of the impact on Cytokine Levels in Tears (IL-4, IL-5, IL-13)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098591
Enrollment
Unknown
Registered
2025-03-11
Start date
2025-03-15
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic conjunctivitis

Interventions

IPL Group:On the basis of the treatment with emestine fumarate eye drops, three intense pulsed light treatments were added, with an interval of 2 weeks between each treatment, and the treatment parame
control group:Use emestine fumarate eye drops alone twice a day for 6 weeks.

Sponsors

Guigang Donghui Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age>=18 years old, gender is not limited. 2. Meet the diagnostic criteria for allergic conjunctivitis, and the assessment of symptoms and signs should be consistent with the self-assessment of symptoms such as itching and other symptoms with a score of more than 2 or 1 or higher in the evaluation of conjunctival hyperemia. 3. No use of relevant anti-allergic and hormone drugs in the past 2 weeks (if there are related drugs, normal saline will be eluted for 1 week after enrollment). 4. Sign the informed consent form and comply with the research regulations.

Exclusion criteria

Exclusion criteria: 1. History of surgery or eye damage that affects eyelid function. 2. Conditions that are not suitable for IPL treatment (such as sensitive skin, systemic erythrin, purpura, etc.). 3. Pregnant and lactating women. 4. Those who have received microplastic injection fillers on the face. 5. Patients with intraocular pressure exceeding the normal range.

Design outcomes

Primary

MeasureTime frame
Cytokine Levels IL-4 in Tears ;Cytokine Levels IL-5 in Tears ;Cytokine Levels IL-13 in Tears ;

Countries

China

Contacts

Public ContactXiao Ma

Guigang Donghui Hospital

2822371613@qq.com+86 185 9010 3625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026